After a year of notable contribution to company growth as Head of Sites, Ninon Armbrust will continue as Managing Director of FutureMeds Germany.
In this role as Managing Director of FutureMeds Germany, Ninon Armbrust will lead the company's strategic expansion across Germany, focusing on geographical growth and therapeutic capabilities expansion.
"Ninon has demonstrated strong leadership qualities in her role as Head of Sites, where she drove remarkable growth, including the successful launch of our Frankfurt site and significant performance improvements in Berlin. Her ability to inspire teams, deliver results, and foster a culture of progress makes her the ideal leader to spearhead our German expansion."
— Wojciech Szczepanik PhD, Executive VP of Site Operations
Under Ninon's leadership, FutureMeds look forward to growing FutureMeds Germany’s geographical footprint and therapeutic capabilities while continuing to develop top talent and deliver industry-leading performance.
With over 10 years of experience in clinical research, Ninon has made a significant impact at Futuremeds Germany. Under her leadership as Head of Sites and her truly “people-oriented” approach, the Berlin site team reached a new performance level and set new standards for operational excellence. She also opened a second location in Frankfurt, setting the stage for further growth in the country.
“I am incredibly proud of what we have achieved so far at Futuremeds Germany, and I am truly grateful for the opportunity to continue growing within the company. After the successful opening of our second site in Germany, we will further expand and strengthen the therapeutic area capabilities including oncology at our sites, while increasing contribution to research. I look forward to leading this exceptional team as we deliver on these key initiatives.”
— Ninon Armbrust, Managing Director of FutureMeds Germany
Follow us on LinkedIn
Follow FutureMeds on LinkedIn and join a growing group of engaged, passionate healthcare and pharmaceutical professionals who are on a mission to accelerate the drug development process and achieve regulatory approval faster so patients can safely access the very latest treatments as soon as possible.
Comentarios